Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (BIVI) is a clinical-stage biotechnology company pioneering novel therapies for chronic liver disease complications and neurodegenerative disorders. This page serves as the definitive source for all official company updates, including clinical trial progress, regulatory milestones, and strategic developments.
Access real-time announcements about BIV201 for liver ascites management and bezisterim for Alzheimer’s/Parkinson’s research. Stay informed on orphan drug designations, partnership agreements, and financial disclosures that shape BioVie’s innovative pipeline.
All content is rigorously curated to provide investors and researchers with compliant, actionable insights. Bookmark this hub for authoritative updates on therapies addressing critical unmet medical needs through advanced clinical research.
BioVie announced promising results from a Phase 2a trial of their drug bezisterim for Parkinson's disease. Data presented at the XXIX World Congress on Parkinson's Disease and Related Disorders showed that patients treated with bezisterim in combination with levodopa/carbidopa experienced significant improvements in both motor and non-motor symptoms compared to placebo. Notably, bezisterim-treated patients saw a -2.8 point improvement on the motor section of the MDS-UPDRS scale. For patients under 70, the improvement was -4.7 points. Additionally, bezisterim-treated patients showed significant gains in sleep/fatigue and leg restlessness symptoms. These findings suggest bezisterim's potential as an adjunct therapy, warranting further investigation in late-phase trials.
BioVie Inc. (NASDAQ: BIVI) secured up to $13.1 million from the U.S. Department of Defense for a Phase 2b clinical trial evaluating bezisterim (NE3107) in treating long COVID symptoms. Long COVID is a condition where symptoms persist post SARS-CoV-2 infection. The trial aims to assess the drug's effectiveness in reducing neurological symptoms associated with long COVID. Bezisterim, an anti-inflammatory and insulin-sensitizer capable of permeating the blood-brain barrier, targets inflammation, a key factor in long COVID. The trial is expected to begin in early 2025 and includes 200 patients.
FAQ
What is the current stock price of Biovie (BIVI)?
What is the market cap of Biovie (BIVI)?
